Protocol Ledger

NCT04198363 · Phase III · COMPLETED

A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection

Interventional Phase III clinical trial protocol NCT04198363 sponsored by Takeda in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-04-30 Enrollment: 510 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04198363
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)510 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04198363
Protocol FieldVerified Registry Value
NCT IdentifierNCT04198363
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment510 participants (ACTUAL)
Registered Start Date2020-04-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI